A Race Against Blindness Grants $1 Million Supporting Axovia Therapeutics’ Planned Clinical Trial for Bardet-Biedl Syndrome (BBS)

Contributed by: GlobeNewswire

Tags

clinical Research

More Like This

Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT

ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

BD² Expands Foundational Effort to Understand Biology of Bipolar Disorder with $36 Million in New Grants

PR Newswire associated0

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

PR Newswire associated0

Foundation Fighting Blindness Expands Giving Opportunities with Enhanced Financial Institution Access for Donor-Advised Funds, Stock Donations, and Cryptocurrency

Business Wire logo

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

PR Newswire associated0

Department of Health - Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases